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Counterregulation by the Coreceptors
CD19 and CD22 of MAP Kinase Activation
by Membrane Immunoglobulin
Reuben M. Tooze,* Gina M. Doody,* et al., 1995), following its tyrosine phosphorylation by
mIg, with which a portion of the CD22 molecules associ-and Douglas T. Fearon
Wellcome Trust Immunology Unit ate (Schulte et al., 1992; Peaker and Neuberger, 1993;
Leprince et al., 1993). The ligands for CD22 are glyco-Department of Medicine
University of Cambridge School of Clinical conjugates containing a 2,6-linked sialic acid expressed
by lymphocytes (Sgroi et al., 1993; Powell and Varki,Medicine
Cambridge CB2 2SP 1994; Kelm et al., 1994). It has been proposed (Doody
et al., 1995) that the sequestration of CD22 from mIg,United Kingdom
as might occur within a lymphoid microenvironment,
enhances the proliferative response of B lymphocytes
by releasing mIg from the inhibitory effects of SHP-1Summary
(Campbell and Klinman, 1995; Cyster and Goodnow,
1995; Doody et al., 1995). Although CD22 has alsoThe signaling pathways linked to membrane immuno-
been proposed to be a positive regulator of signalingglobulin (mIg) that are regulated by the coreceptors
(Tuscano et al., 1996a), the recent findings that CD22-CD19 and CD22 are not known. The mitogen-activated
deficient B lymphocytes display enhanced Ca21 re-protein (MAP) kinases ERK2, JNK, and p38 couple ex-
sponses to ligated mIg and have a surface phenotypetracellular signals to transcriptional responses. The
suggestive of chronic in vivo stimulation are more easilycapacity of mIg to activatethese MAP kinases is syner-
explained by a negative regulatory function for this core-gistically amplified by coligating CD19, and this effect
ceptor (O'Keefe et al., 1996; Otipoby et al., 1996; Satorequires that CD19 be juxtaposed to mIg. CD22 sup-
et al., 1996; Nitschke et al., 1997).presses MAP kinase activation when cross-linked to
The signaling pathways linked to mIg that are subjectmIg alone or to the coligated complex of mIg and
to the regulatory effects of CD19 and CD22 have notCD19. Separate ligation and sequestration of CD22
been identified. Eukaryotic cells use evolutionarily con-from mIg enhances MAP kinase activation, probably
served MAP kinase cascades to translate extracellularreflecting release of mIg from constitutive down-regu-
stimuli into signals that induce the transcriptionof geneslation. Thus, CD19 and CD22 have counterregulatory
(Treisman, 1996; Su and Karin, 1996). Three interactingeffects on MAP kinase activation by mIg, which are
cascades activate the MAP kinases ERK, JNK, and p38,dependent on their proximity to the antigen receptor.
which stimulate transcription factors having distinct
DNA-binding specificities. Therefore, different patternsIntroduction
of MAP kinase activation may lead to differential expres-
sion of genes and contrasting cellular phenotypes, suchActivation of the B lymphocyte occurs by the integration
as growth or apoptosis (Xia et al., 1995). In B lympho-of signals from membrane immunoglobulin (mIg) and its
cytes, mIg has been shown to activate ERK2 (Casillascoreceptors, the CD19/CD21 complex and CD22, which
et al., 1991; Gold et al., 1992; Kim et al., 1993; Tordai etenables the evaluation of not only the structural charac-
al., 1994) and, less effectively, JNK and p38 (Li et al.,teristics of an antigen but also certain of its biological
1996; Sutherland et al., 1996). In contrast, CD40 is afeatures. The CD19/CD21 complex examines the possi-
potent activator of JNK and p38 and a less efficientble microbial origin of antigen. CD21 is the receptor for
stimulant of ERK (Berberich et al., 1996; Kashiwada etthe C3d fragment of complement, an innate immune
al., 1996; Li et al., 1996; Sakata et al., 1995; Sutherlandsystem which covalently attaches the C3d protein to
et al., 1996). For comparison, in T lymphocytes the Tmicrobial antigens. Antigen bearing C3d coligates the
cell receptor activates only ERK (Izquierdo et al., 1993;CD19/CD21 complex to mIg, lowering the threshold for
Franklin et al., 1994; Su et al., 1994), and activation ofcellular activation (Dempsey et al., 1996). This function
JNK requires costimulation with CD28 (Su et al., 1994).of the complex is essential for a normal immune re-
In the present study, the ability of mIg to activatesponse, as exemplified by the finding of impaired anti-
ERK2, JNK, and p38 is shown to be synergistically aug-body responses to T lymphocyte-dependent antigens
mented by coligation of CD19. This effect is reversed byin mice lacking either CD21 (Ahearn et al., 1996) or CD19
the additional coligation of CD22, indicating that these(Engel et al., 1995; Rickert et al., 1995). Amplification
coreceptors have counterregulatory effects on signalingof mIg signaling by the CD19/CD21 complex may be
when juxtaposed to mIg. However, when CD22 is se-mediated by the cytosolic proteins phosphatidylinositol
questered from mIg, the activation of MAP kinases is3-kinase (PI3K; Chalupny et al., 1993; Tuveson et al.,
enhanced, giving CD22 the apparent potential for both1993) and Vav (Weng et al., 1994), which bind to tyrosine
up- and down-regulation of B cell activation.phosphorylated CD19.
CD22 may indicate to the B lymphocyte its presence
within a secondary lymphoid organ. This coreceptor reg- Results
ulates signaling by recruiting the inhibitory tyrosine
phosphatase SHP-1 (Campbell and Klinman, 1995; Doody To determine whether CD19 regulates MAP kinase acti-
vation by mIg, purified murine splenic B lymphocytes
were pretreated with variable amounts of biotinylated*These authors contributed equally to this work.
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Figure 1. Synergistic Activation of ERK2, JNK, and p38 Induced by Coligating CD19 to Incremental Numbers of mIg
B lymphocytes were preincubated with biotinylated irrelevant control Fab, incremental concentrations of Fab anti-k, Fab anti-CD19, or anti-
CD19 and anti-k together. The cells were washed, stimulated by addition of avidin, and lysed. ERK2, JNK, and p38 were immunoprecipitated,
and the precipitates were assayed for kinase activity using GST-Elk1C, GST-c-Jun1±194, and GST-ATF2C2 fusion proteins, respectively, as
substrates. The kinase reaction products were resolved by SDS-PAGE and their phosphorylation was quantitated by (A) autoradiography and
(B) assay of [32P] by InstantImager. The activities of JNK, ERK2 and p38 from B lymphocytes stimulated with anti-k alone (open squares) or
together with anti-CD19 (closed squares) are shown relative to stimulation with control Fab.
Fab antibody to the k light chain alone, or together with ligated individually or together for 2, 4, and 10 min,
followed by immunoprecipitation and functional assaya constant amount of biotinylated Fab antibody toCD19.
The cell-bound antibodies were cross-linked by addition of the MAP kinases. When cells were stimulated by mIg
alone, activation of ERK2 was maximal at 2 min, afterof avidin at zero time. After 10 min, the cells were lysed;
ERK2, JNK, and p38 were immunoprecipitated with spe- which activity rapidly declined to a lower, but sustained,
plateau level (Figure 3). CD19 alone did not activatecific antibodies; and the immunoprecipitates were as-
sayed for the activities of these kinases by their ability ERK2. Costimulation by CD19 and mIg augmented acti-
vation of ERK2 at 2 min and, despite a fall after thisto phosphorylate thesubstrates Elk-1, c-Jun, and ATF-2,
respectively (Treisman, 1996; Su and Karin, 1996). Ligat- time, maintained activity at levels that were .5-fold
above those of unstimulated cells at 4 and 10min. There-ing mIg alone modestly activated ERK2 and p38, but
not JNK (Figure 1). In other experiments, JNK activity fore, coligating CD19 to mIg amplified both early and
late ERK2 activity. The kinetics of JNK activation, whichwas slightly increased by ligating mIg (not shown). Co-
ligating CD19 to mIg synergistically activated all three occurred only with costimulation by mIg and CD19, were
distinct from those of ERK2, being undetectable at 2MAP kinases, both lowering the thresholds for activa-
tion and increasing the magnitude of the responses. min, slight at 4 min, and marked at 10 min. The activation
of p38 exhibited a third pattern in which both mIg andLigating CD19 alone activated only p38, and this activity
was ,2-fold that of p38 from unstimulated cells. CD19 alone induced responses at 2 min that declined
at 4 and 10 min, similar to the effect of mIg on ERK2.This effect of CD19 was further examined by pretreat-
ing B lymphocytes with variable concentrations of bio- Coligating CD19 to mIg, however, increased activation
of p38 at 2 min and prevented the subsequent decreasetinylated antibody to CD19 alone, or together with a
single concentration of biotinylated antibody to k. The observed with mIg and CD19 alone.
The kinetics of ERK2 activation by mIg varies withcell-bound antibodies were cross-linked for 10 min by
addition of avidin, the cells were lysed, and the MAP the type of crosslinking reagent used. As previously
demonstrated by others (Kashiwada et al., 1996; Suther-kinases were functionally assayed. Enhanced activation
of ERK2, JNK, and p38 occurred in parallel when in- land et al., 1996), stimulation of mIg by a polyclonal
antibody, F(ab9)2 goat anti-mIgM, induced rapid and sus-creased amounts of CD19 were coligated to mIg (Figure
2). CD19 again was relatively ineffective when ligated tained activation of ERK2. However, even with this mode
of mIg crosslinking, JNK and p38 activities did not ex-alone.
The kinetics of costimulation of MAP kinases were ceed 2-fold above background (data not shown).
To compare the effects of CD22 with those of CD19 onexamined with B lymphocytes having mIg and CD19
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Figure 2. Synergistic Activation of ERK2, JNK, and p38 Induced by Coligating mIg to Incremental Amounts of CD19
B lymphocytes were preincubated with biotinylated nonspecific control Fab, incremental concentrations of Fab anti-CD19, Fab anti-k, or
anti-k and anti-CD19 together. After stimulation by addition of avidin, ERK2, JNK, and p38 were assayed as in Figure 1.
(A) Autoradiographs demonstrating phosphorylation of the MAP kinase substrates.
(B) The activities of JNK, ERK2, and p38 from B lymphocytes stimulated with anti-CD19 alone (open squares) or with anti-k (closed squares)
relative to stimulation with control Fab.
MAP kinase activation, B lymphocytes were pretreated CD22 can reverse the augmenting effect of CD19 on
mIg signaling.with biotinylated Fab antibodies of irrelevant specificity,
anti-k, anti-CD19, and anti-CD22, alone or in various To examine whether the spatial relationships of CD19
and CD22 to mIg determined the outcome of their liga-combinations. Cell-bound antibodies were cross-linked
for 10 min by addition of avidin, the cells were lysed, tion, B lymphocytes were preincubated with biotin-
ylated antibodies to CD19 or CD22, or with biotinylated,and the MAP kinases were immunoprecipitated and as-
sayed. Ligating mIg alone caused a 7-fold increase in isotype control antibodies. Microbeads bearing avidin
were added and allowed to adhere to the cells for 10 min;ERK2 activity, and an z2-fold increase in JNK and p38
activities relative to the effects of control Fab (Figure 4). adherence was confirmed by microscopic examination.
Activation was induced by addition of soluble goatLigating CD19 and CD22 alone caused modest or no
activation of the MAP kinases. Coligating control Fab F(ab9)2 antibody to mIg. After 10 min, the cells were
lysed, and the activities of the MAP kinases were mea-to mIg was without effect. In contrast, coligating CD19 to
mIg again increased activation of all three MAP kinases, sured. In contrast to the effects of coligation, crosslink-
ing CD19 independently of mIg caused no enhance-whereas crosslinking CD22 to mIg suppressed activa-
tion of ERK2 and did not enhance activation of either ment, and perhaps slight inhibition, of MAP kinase
activity relative to theeffects of ligating mIg alone (FigureJNK or p38.
We determined whether recruiting CD22 to a costimu- 6A). Ligating CD22 alone caused modest activation of
ERK2, JNK, and p38 and, when combined with separatelatory complex of mIg and CD19 onB lymphocytes inhib-
ited the augmented activation of MAP kinases. B lym- ligation of mIg, augmented, rather than suppressed, the
activation of the MAP kinases (Figure 6B). Thus, thephocytes were pretreated with biotinylated antibodies
to k and CD19 in theabsence or presence of incremental effect of ligating CD19 and CD22 on MAP kinase activa-
tion by mIg depends on thespatial relationships of theseconcentrations of antibody to CD22, or of antibody to
MHC class I, as a control. The concentration of antibody coreceptors to mIg.
to k was suboptimal and less than that required for MAP
kinase activation alone. The cell-bound antibodies were Discussion
cross-linked by addition of avidin, and MAP kinase ac-
tivities were assayed. Crosslinking CD22, but not MHC The present study advances the understanding of three
questions regarding the regulation by CD19 and CD22 ofclass I, to the coligated k and CD19 suppressed the
activation of ERK2, JNK, and p38 in a dose-related B lymphocyte activation by mIg. First, can a biochemical
pathway of intracellular signaling, potentially leading tomanner (Figure 5). Therefore, the inhibitory effect of
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coligation to mIg lowered the threshold for cellular prolif-
eration induced by mIg (Carter and Fearon, 1992), and
genetic deletion suppressed the response to T-depen-
dent antigens in vivo (Engel et al., 1995; Rickert et al.,
1995), have indicated that it is a positive regulator. The
present study extends this concept by demonstrating
that recruiting CD19 to the mIg signaling complex in-
duces activation of three MAP kinases, at suboptimal
levels of mIg ligation that alone would be non-activating,
by increasing the magnitude and extending the duration
of MAP kinase activation, relative even to the effects of
ligating optimal numbers of mIg alone.
Specific downstream events associated with MAP ki-
nase activation in the B lymphocyteare not known. How-
ever, the capacity of coligated CD19 to activate JNK
enables mIg to share with CD40 the stimulation of this
MAP kinase (Berberich et al., 1996; Li et al., 1996; Sakata
et al., 1995; Sutherland et al., 1996), which correlates
with the ability of CD40 to prevent apoptosis of germinal
center B lymphocytes (Liu et al., 1989). Since the rela-
tively few T cells that are present in the germinal center
and are capable of presenting CD40L are located in the
outer zone (Casamayor-Palleja et al., 1995), and since
CD19 is required for the normal development of this
structure (Engel et al., 1995; Rickert et al., 1995), it is
possible that this function of CD19 may maintain the
viability of antigen-specific centrocytes. Consistent with
this possibility is the report that coligating CD21 to mIg
suppresses apoptosis of resting splenic B cells and
WEHI231 cells (Kozono et al., 1995).
The only biochemical response previously shown to
be enhanced by coligating CD19 with mIg, either directly
or indirectly through its association with CD21, was an
increase in free intracellular [Ca21] (Carter et al., 1991).
Of the many intracellular reactions that are mediated by
intracellular Ca21, that which is perhaps most relevant
to the present study is the activation of calcineurin,
which leads to the translocation of NFAT1 to the nucleus
(Clipstone and Crabtree, 1992; Jain et al., 1993). Be-
cause NFAT1 binds cooperatively with c-jun in the distal
IL-2 promoter in T cells (Jain et al., 1995), the new finding
that CD19 costimulates the activation of JNK, which
induces the transcriptional activity of c-jun (Treisman,
1996; Su and Karin, 1996), suggests that a role for CD19
in the B lymphocyte may be the induction of genes
Figure 3. Kinetics of Activation of ERK2, JNK, and p38
having promoters similar to those of the IL-2 gene. Al-
B lymphocytes were preincubated with biotinylated irrelevant Fab, though these genes have not been identified, the inhibi-
Fab anti-k (5 mg/ml; open squares), Fab anti-CD19 (0.5 mg/ml; open
tion by cyclosporin A of B lymphocyte proliferationcircles), and anti-k and anti-CD19 together (closed triangles), re-
caused by ligating mIg (Dongworth and Klaus, 1982;spectively, followed by addition of avidin. Samples of cells were
removed at timed intervals, and the activities of ERK2, JNK, and Muraguchi et al., 1983) predicts their existence and bio-
p38 were assayed and expressedrelative to lymphocytes stimulated logical importance.
with control Fab. The present study has not addressed the mechanism
by which CD19 costimulates the activation of MAP ki-
nases by mIg. The association of Lyn with the cyto-
altered transcription of genes, that is regulated by CD19 plasmic domain of CD19 (van Noesel et al., 1993) would
and CD22 be identified? Second, do the spatial rela- not seem to account for this function as CD19 alters the
tionships of the coreceptors to mIg determine their nature of the signal induced by mIg, rather than simply
ability to modulate signaling? Third, how can a corecep- changing its threshold. For example, increasing the
tor apparently have both positive and negative regula- ligation of mIg to saturating levels did not cause activa-
tory functions? tion of ERK2, JNK, or p38 that was comparable in
Although CD19 was first described as a membrane magnitude or duration to that occurring with coligated
protein that inhibited activation of the B lymphocyte mIg and CD19. It seems more likely that the recruitment
by CD19 of PI3K (Chalupny et al., 1993; Tuveson et al.,(Pezzutto et al., 1987), the subsequent findings that its
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Figure 4. Comparison of the Effects of Coli-
gating CD19 and CD22, Respectively, to mIg
on MAP Kinase Activation
B lymphocytes were preincubated with 5 mg/
ml biotinylated nonspecific control Fab, Fab
anti-k, Fab anti-CD19, Fab anti-CD22, or
combinations of these antibodies; washed;
and stimulated for 10 min by addition of avi-
din. Lysates of cells were prepared andERK2,
JNK, and p38 were assayed. Shown are the
autoradiographs of the phosphorylated MAP
kinase substrates and their relative incorpo-
ration of [32P].
1993), Vav (Weng et al., 1994), or both may contribute by the ratio of CD19 and CD22 molecules that are juxta-
posed to the mIg signaling complex. This, in turn, willto this costimulatory function, since both have been
shown in other systems to regulate the activation of be governed by the relative presence of their respective
ligands that are directly or indirectly associated with theRas and Rac (Valius and Kazlauskas, 1993; Hawkins et
al., 1995; Hu et al., 1995; Crespo et al., 1996; Klippel antigen.
A positive signaling function for CD22 had been pre-et al., 1996; Olson et al., 1996; Reif et al., 1996; Crespo
et al., 1997), which are upstream of ERK, JNK, and possi- dicted, based on studies demonstrating enhanced B
cell responses to mIg when CD22 was separately ligatedbly p38 (Treisman, 1996; Su and Karin, 1996). This func-
tion of CD19 does require that it be coligated to mIg, a (Pezzutto et al., 1988; Tuscano et al., 1996a), on the
association of CD22 with Lyn, Syk, and PI3K (Law et al.,finding that had been predicted on the basis of earlier
studies of the role of CD19 in B lymphocyte proliferation 1996; Tuscano et al., 1996b), and on the impairment of
some mIg-dependent responses of CD22-deficient B(Carter and Fearon, 1992) and of the capacity of C3d-
coated antigen to crosslink the CD19/CD21 complex to lymphocytes (Otipoby et al., 1996; Sato et al., 1996). The
present study affirms that separate ligation of CD22,mIg (Dempsey et al., 1996). Interestingly, CD28, which
costimulates JNK activation in the T cell (Su et al., 1994), with or without coincident ligation of mIg, may activate
the B lymphocyte, at least with respect to MAP kinases.may be ligated separately from the T cell receptor, sug-
gesting that CD19 and CD28 may have different mecha- However, as previously suggested (Doody et al., 1995,
1996), this apparent positive signaling function of CD22nisms for augmenting activation of this MAP kinase. The
slight decrement in mIg-dependent activation of ERK2 may be caused by the sequestration of SHP-1 from mIg,
leading to enhanced signaling by the derepressed mIgand p38, when CD19 was separately ligated, may reflect
the participation in mIg signaling of small numbers of complex. In support of this explanation are the findings
that B lymphocytes lacking CD22 have an activated phe-CD19 that are constitutively associated with the antigen
receptor (Carter et al., 1997). notype (O'Keefe et al., 1996; Otipoby et al., 1996; Sato
et al., 1996; Nitschke et al., 1997). Thus, genetic deletionCD22, as was predicted by its association with SHP-1
(Campbell and Klinman, 1995; Doody et al., 1995) and or sequestration of CD22 releases mIg from down-regu-
lation by those coreceptors that are constitutively asso-by the enhanced activation of CD22-deficient B cells in
vitro and in vivo (O'Keefe et al., 1996; Otipoby et al., ciated with the antigen receptor.
The potent and opposing effects of CD19 and CD221996; Sato et al., 1996; Nitschke et al., 1997), is an inhibi-
tor of MAP kinase activation by mIg. Inhibition was most on the intracellular pathways of MAP kinase activation
emphasize their potential roles in determining whetherdirectly demonstrated by coligating CD22 to mIg, which
might occur physiologically through the constitutive as- the B lymphocyte responds to antigen. Further under-
standing of their biological roles in the immune responsesociation of CD22 with mIg (Peaker and Neuberger,
1993; Leprince et al., 1993) or by the presence of CD22 must move proximally to analysis of the expression of
their ligands, and distally to defining the genes that areligands on cells presenting antigen to B lymphocytes
(Doody et al., 1996). This inhibitory function of CD22 not transcribed in response to these MAP kinases.
only suppressed signaling by mIg alone, as assessed
by diminished activation of ERK2, but also reversed the Experimental Procedures
enhanced activation of all three MAP kinases by the
Antibodies, Proteins, and Reagentscross-linked complex of CD19 and mIg. It is most likely
Rabbit polyclonal antibody to mouse ERK2 was purchased fromthat these effects of CD22 occur throughdirect inhibition
Upstate Biotechnology and used in the experiments depicted inof the mIg complex, on which the signaling function of
Figures 2±6; serum 122 rabbit polyclonal anti-ERK2 was provided
CD19 is dependent. The opposing, dose-related effects by Dr. Christopher J. Marshall (Leevers and Marshall, 1992) and
of CD19 and CD22 on mIg signaling suggest that the used in the experiment depicted in Figure 1. G151±333.8 mouse anti-
JNK1 was purchased from Pharmingen and used in the experimentsnetoutcome of MAP kinase activation will be determined
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Figure 6. Effects on MAP Kinase Activation of Separately Ligating
mIgM, CD19 (A), and CD22 (B)
B lymphocytes were preincubated for 10 min with 10 mg/ml biotinyl-
ated, isotype matched control antibodies, anti-CD19, or anti-CD22,
respectively, followed by an additional 10 min in the presence of
beads bearing avidin. Adherence of the beads to cells preincubated
with anti-CD19 or anti-CD22 was confirmed by light microscopy.
The cells were stimulated for 10 min by addition of 10 mg/ml goat
F(ab9)2 anti-IgM and were assayed for MAPK activation. Activities
Figure 5. Suppression by CD22 of MAP Kinase Activation Induced are shown relative to that of cells incubated with control antibodies
by Coligating CD19 and mIg and beads.
B lymphocytes were preincubated with biotinylated control Fab (0.5
mg/ml), with Fab anti-k (0.1 mg/ml) and Fab anti-CD19 (0.5 mg/ml)
together, or with anti-k and anti-CD19 in the presence of incremental
CD22 (Lyb-8.2), 107.3 mouse IgG1 purified myeloma protein, andconcentrations of Fab anti-CD22 (closed squares) or Fab anti-MHC
34±2±12 mouse IgG2a antibody to mouse H-2Dd (Pharmingen) wereclass I (open squares). After stimulation with avidin, the activities
used. Fab fragments were produced according to standard proce-of ERK2, JNK, and p38 were assayed and are shown relative to that
dures (Harlow and Lane, 1988), and antibodies and Fab fragmentsof the control Fab stimulation. Equivalent binding of MHC class I
were biotinylated with ImmunoPure Sulfo-NHS-Biotin (Pierce). Poly-and CD22 antibodies was confirmed by staining with avidin-FITC
bead carboxylated microspheres (Polysciences, Inc.) and avidinand flow cytometry (data not shown).
(Sigma) were coupled according to the manufacturer's instructions.
The construct for GST-Elk1C was provided by Dr. Richard Treisman
(Marais et al., 1993), for GST-c-Jun1±194 by Dr. Doreen Cantrell (Hill
depicted inFigures 1±3;SAK9 rabbit antibodyagainst the C terminus et al., 1995), and for GST-ATF2C2 by Dr. Nic Jones (Livingstone et
of p54 SAPKa was provided by Dr. Jeremy Saklatvala and used in
al., 1995). Glutathione-Sepharose and GammaBind Plus Sepharose
the experiments depicted in Figures 4±6. SAK7 rabbit anti-p38 was
were purchased from Pharmacia Biotech.
also provided by Dr. Jeremy Saklatvala (Saklatvala et al., 1996).
Goat F(ab9)2 antibody to mouse IgM (Jackson Immunoresearch),
1D3 rat IgG2a antibody to mouse CD19 (Krop et al., 1996), LO-MK-1 Cell Purification
BALB/c mice (8±14 weeks of age) were purchased from Harlan andrat IgG2a antibody to mouse k light chain and IR 418 rat IgG2a
myeloma (Zymed), Cy34.1 mouse IgG1 antibody against mouse housed according to standard U.K. Home Office guidelines. Splenic
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B lymphocytes were isolated by depletion of T cells with anti-Thy that can be enhanced by the membrane IgM complex. J. Immunol.
147, 3663±3671.1.2 mAb (Sigma) and rabbit complement (Harlan SeraLab).
Carter, R.H., Doody, G.M., Bolen, J.M., and Fearon, D.T. (1997).
B Lymphocyte Stimulation Membrane IgM-induced tyrosine phosphorylation of CD19 requires
For the experiments depicted in Figures 1±5, B lymphocytes were a CD19 domain that mediates association with components of the
preincubated with appropriate combinations of biotinylated Fab B cell antigen receptor complex. J. Immunol. 158, 3062±3069.
fragments of antibodies to k, CD19, CD22, MHC class I or irrelevant Casamayor-Palleja, M., Khan, M., and MacLennan, I.C. (1995).
specificity. After 10 min, the cells were washed, stimulated by addi- A subset of CD41 memory T cells contains preformed CD40 ligand
tion of 20 mg/ml avidin for timed intervals until the addition of an that is rapidly but transiently expressed on their surface after
equal volume of 23 lysis buffer. activation through the T cell receptor complex. J. Exp. Med. 181,
In the experiment shown in Figure 6, B lymphocytes were preincu- 1293±1301.
bated with biotinylated, isotype matched control antibodies, anti-
Casillas, A., Hanekom, C., Williams, K., Katz, R., and Nel, A.E. (1991).CD19, or anti-CD22 for 10 min, followed by 10 min in the presence
Stimulation of B-cells via the membrane immunoglobulin receptor orof beads bearing avidin. Cells were then stimulated by addition of
with phorbol myristate 13-acetate induces tyrosine phosphorylationF(ab9)2 goat anti-mouse IgM for 10 min. and activation of a 42-kDa microtubule-associated protein-2 kinase.
J. Biol. Chem. 266, 19088±19094.
In Vitro Kinase Assays
Chalupny, N.J., Kanner, S.B., Schieven, G.L., Wee, S.F., Gilliland,After stimulation, cells were lysed in ice-cold lysis buffer containing
L.K., Aruffo, A., and Ledbetter, J.A. (1993). Tyrosine phosphorylation1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 100 mM Tris (pH
of CD19 in pre-B and mature B cells. EMBO J. 12, 2691±2696.7.4), 150 mM NaCl, 1 mM EDTA, 10 mM Na4P2O7, 25 mM sodium
Clipstone, N.A., and Crabtree, G.R. (1992). Identification of cal-b-glycerophosphate, 100 mM sodium orthovanadate, 10 mm leupep-
cineurin as a key signalling enzyme in T-lymphocyte activation. Na-tin, 2 mg/ml antipain, 1 mM pepstatin A, 6 mg/ml chymostatin, 1
ture 357, 695±697.mg/ml aprotinin, and 1 mg/ml 4-(2-aminoethyl)-benzenesuflonyl fluo-
ride (Calbiochem). Lysates were clarified by centrifugation at 48C, Crespo, P., Bustelo, X.R., Aaronson, D.S., Coso, O.A., Lopez-Bara-
hona, M., Barbacid, M., and Gutkind, J.S. (1996). Rac-1 dependentand equal protein content was confirmed by BCA assay (Pierce).
stimulation of the JNK/SAPK signaling pathway by vav. OncogeneLysates were divided into three replicate samples and incubated
13, 455±460.with antibodies specific for the MAP kinases, followed by Gam-
maBind Plus Sepharose (Pharmacia). Immunoprecipitates were Crespo, P., Schuebel, K.E., Ostron, A.A., Gutkind, J.S., and Bustelo,
washed twice with lysis buffer and twice with kinase buffer (20 X.R. (1997). Phosphotyrosine-dependent activation of Rac-1 GDP/
mM Hepes [pH 7.6], 20 mM MgCl2, 2 mM DTT, 20 mM sodium GTP exchange by the vav proto-oncogene product. Nature 385,
b-glycerophosphate, 20 mM p-nitrophenylphosphate, and 100 mM 169±172.
sodium orthovanadate). Kinase assays were performed (Derijard et Cyster, J.G., and Goodnow, C.C. (1995). Protein tyrosine phospha-
al., 1994) using GST-Elk1C (Marais et al., 1993), GST-c-Jun1±194 tase 1C negatively regulates antigen receptor signaling in B lympho-
(Hill et al., 1995), and GST-ATF2C2 (Livingstone et al.,1995) fusion cytes and determines thresholds for negative selection. Immunity
proteins as substrates for ERK2, JNK, and p38, respectively. Immu- 2, 13±24.
noprecipitates were resuspended in 80 ml kinase buffer containing
Dempsey, P.W., Allison, M.E., Akkaraju, S., Goodnow, C.C., and
10±20 mg of fusion protein, 20 mM ATP, and 5 mCi [g-32P] ATP. After
Fearon, D.T. (1996). C3d of complement as a molecular adjuvent:20 min at room temperature, 40 ml 43 SDS sample buffer was
bridging innate and acquired immunity. Science 271, 348±350.added, the samples were boiled, and the kinase reaction products
Derijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin,were resolved by SDS-PAGE. Equal loading of fusion protein and
M., and Davis, R.J. (1994). JNK1: a protein kinase stimulated by UVprecipitating antibody was confirmed by Coomassie stain, and
light and Ha-ras that binds and phosphorylates the c-Jun activationphosphorylation of the fusion protein bands was quantitated using
domain. Cell 73, 1025±1037.a Packard-Bell InstantImager.
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